TrialHuman vaccines & immunotherapeutics2025

Immunogenicity, safety, and tolerability of a β-glucan-CpG-adjuvanted respiratory syncytial virus vaccine in Japanese healthy participants aged 60 to 80 years: A phase 2, randomized, double-blind, dose-finding study.

Tetsuo Nakayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.